论文部分内容阅读
目的:观察不同剂量干扰素治疗慢性乙型病毒性肝炎时血清2′,5′-寡腺苷酸合成酶(2′,5′-OAS)的变化,了解细胞抗病毒状态建立与乙肝病毒复制的关系。方法:32例慢性乙肝患者随机分为3蛆,即1MU干扰素腹腔注射11例(治疗Ⅰ组),3MU干扰素皮下注射11例(治疗Ⅱ组),分别连续注射5天,以后每周3次,共16周,并与不用干扰素治疗的10例(对照组)作对比,通过2′,5′-OAS、ALT、HBeAg、HBV-DNA(PCR法)连续检测,评价治疗反应。结果:疗程结束时,两治疗组和对照组ALT均下降,3组差异无显著性(P>0.05)。治疗Ⅰ组和治疗Ⅱ组2′,5′-OAS的活性均增加,治疗Ⅰ组在疗程结束时达峰值,治疗Ⅱ组在疗程早期就明显升高,而对照组无升高(P<0.05)。2′,5′-OAS的增幅水平与HBeAg、HBV-DNA的阴转呈相关性。结论,2′,5′-OAS可能是监测干扰素治疗慢性乙型肝炎疗效的有效指标。
OBJECTIVE: To observe the changes of serum 2 ’, 5’-oligoadenylate synthase (2’, 5’-OAS) in the treatment of chronic hepatitis B with different dosages of interferon, and to understand the relationship between cell antiviral status and hepatitis B virus replication Relationship. Methods: Thirty-two patients with chronic hepatitis B were randomly divided into 3 groups: 1 case received intraperitoneal injection of 1 MU of interferon (Group Ⅰ), 11 cases of subcutaneous injection of 3MU interferon (Group Ⅱ) received continuous injection for 5 days and 3 A total of 16 weeks, compared with 10 cases without interferon treatment (control group), the response was evaluated by continuous detection of 2 ’, 5’-OAS, ALT, HBeAg and HBV DNA (PCR). Results: At the end of the course of treatment, ALT decreased in both treatment and control groups, with no significant difference between the three groups (P> 0.05). The activity of 2 ’and 5’-OAS in treatment group Ⅰ and treatment group Ⅱ increased. The treatment group Ⅰ peaked at the end of the treatment period. The treatment group Ⅱ increased significantly in the early course of treatment, while the control group did not (P <0.05 ). 2 ’, 5’-OAS increased level and HBeAg, HBV-DNA negative correlation was. Conclusions: 2 ’, 5’-OAS may be an effective indicator to monitor the efficacy of interferon in the treatment of chronic hepatitis B patients.